• Innate Pharma to participate in the 10th Annual SVB Leerink Global Healthcare Conference

    Source: Nasdaq GlobeNewswire / 17 Feb 2021 01:00:00   America/New_York

    Marseille, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior management team are scheduled to participate in the following upcoming virtual investor conference:

          ·10th Annual SVB Leerink Global Healthcare Conference
                Event Date: February 24-26, 2021
                Fireside Chat: February 24, 2021 at 2:00-2:30 p.m. CET / 8:00-8:30 a.m. ET

    A live webcast of the fireside chat will be available through the News & Events page of the Investors section of the Company’s website at www.innate-pharma.com. An archived replay of the webcast will be available for approximately 90 days following the presentation.
                                                                                                                         

    About Innate Pharma:

    Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

    Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

    Innate has been a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

    Headquartered in Marseille, France, with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

    Learn more about Innate Pharma at www.innate-pharma.com

    Information about Innate Pharma shares:

    ISIN code
    Ticker code
    LEI    		FR0010331421
    Euronext: IPH Nasdaq: IPHA
    9695002Y8420ZB8HJE29

    Disclaimer on forward-looking information and risk factors:

    This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts, the Company’s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company’s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2019, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

    This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

    For additional information, please contact:

    Investors

     

    Innate Pharma         

    Tel.: +33 (0)4 30 30 30 30

    investors@innate-pharma.com



     

         		Media

     

    Innate Pharma

    Tracy Rossin (Global/US)

    Tel.: +1 240 801 0076

    Tracy.Rossin@innate-pharma.com

     

    ATCG Press

    Marie Puvieux (France)

    Tel.: +33 (0)9 81 87 46 72

    innate-pharma@atcg-partners.com

    Attachment


Share on,